A Science & Innovation Webinar, presented by GSK.

This educational session provides an up-to-date overview of chronic hepatitis B (CHB), focusing on its epidemiology, disease burden, and the evolving goal of achieving a functional cure. The program highlights the challenges of CHB management, the importance of early detection and guideline-based care, and the psychosocial impact on patients. Current gaps in diagnosis and treatment are discussed, along with the rationale for aiming beyond viral suppression toward functional cure as recommended by global guidelines.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Sanofi.

In this webinar, we will be discussing the following topics around T1D staging, screening, and treatment:

• The role of beta-cell function and C-peptide in disease progression.
• Mechanism of action for teplizumab.
• Efficacy and safety results from teplizumab clinical development program.

This product is indicated for use in State 2 T1D patients aged 8 years and older to delay onset of Stage 3 T1D. The data in this webinar regarding the use in Stage 3 T1D patients is investigational and the safety and efficacy for this use has not been reviewed/approved by the FDA. This information constitutes preapproval information exchange and is intended for formulary/population health decision makers only.

This webinar will provide payer and managed care leaders with a clear, visual map of the precision medicine patient access ecosystem, illuminate the roles and handoffs that drive delays, and define specific payer levers, including equity-focused measures, to reduce friction and accelerate timeline, equitable access.

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. Migraine ranks second worldwide in terms of years lost due to disability. Direct annual all cause healthcare costs for a migraine patient is over twice that of a non-migraine patient. Indirect costs from the impact of the disease on a patient's ability to function (absenteeism and presenteeism) total over $35B annually.

Therefore, it is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal.

A Science & Innovation Webinar, presented by Abbvie.

Parkinson’s disease is a neurodegenerative disorder characterized by the dysfunction and loss of dopamine-producing neurons in the brain, along with the accumulation of Lewy body pathology. The condition leads to a gradual progression of both motor and non-motor symptoms. Although oral dopaminergic drugs provide symptom control for about 3 to 6 years, their benefits decrease over time, resulting in a narrower therapeutic window and worsening symptoms.

Vyalev (Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion) offers the first 24-hour subcutaneous infusion of levodopa-based treatment, specifically designed to help individuals with advanced Parkinson’s Disease experiencing severe motor fluctuations not adequately managed by other therapies.

Join us for an insightful webinar designed especially for pharmacy students embarking on the journey toward managed care pharmacy residency training.

This interactive session features a distinguished panel of Residency Program Directors, who will share guidance on finding the "right fit" program and offer practical strategies for successful engagement throughout the application and interview process. From understanding what programs seek in candidates to tips for making a positive impression, panelists will illuminate both the challenges and opportunities that residency applicants encounter. Attendees will have ample time to ask questions and gain clarity, ensuring a well-equipped plan to navigate each step of the residency pursuit.

Speakers:

Thomas C. Pomfret, PharmD, MPH, BCPS
PGY1 Managed Care Residency Program Director | ForHealth Consulting at UMass Can Medical School

Amanda Bain, PharmD, MPH, MBA
PGY1 Managed Care Residency Program Director | The Ohio State University Health Plan

Spenser Smith, PharmD
PGY1 Managed Care Residency Program Director | BlueCross BlueShield of North Carolina

Ellen M. Feeney, PharmD, BCPS
PGY1 Managed Care Pharmacy Residency Program Director | Highmark Inc.

An AMCP Webinar, hosted by FormularyDecisions®.

Significant policy changes under the new presidential administration are set to impact various healthcare sectors. Upstream influences demand a strategic reevaluation of global supply chains and competitive positioning, while downstream effects will reshape how organizations and communities engage with and serve local populations.

This session will examine the evolving policy landscape and its implications for stakeholders in managed care pharmacy and the biopharmaceutical industry. Through expert insights and dynamic discussion, attendees will gain a practical framework to navigate emerging challenges and opportunities, empowering informed decision-making in a rapidly changing healthcare environment.